
Alumis Inc (ALMS) Stock Forecast & Price Target
Alumis Inc (ALMS) Analyst Ratings
Bulls say
Alumis is expected to see success with its TYK2 inhibitors, envudeucitinib and A-005, as it moves towards patient testing and a potential NDA submission for envu in psoriasis in 4Q26. The company has a strong cash position with $502.3M in cash and investments and a runway into 4Q27, giving it the financial flexibility to pursue its pipeline and explore strategic alternatives for lonigutamab. However, risks include potential delays in regulatory filings, competition, and possible equity dilution risk.
Bears say
Alumis is facing a number of risks and uncertainties that lead to a negative outlook on the stock. Their prospects for expansion beyond their initial psoriasis indication are heavily dependent on the results of the upcoming LUMUS trial. If this trial does not show convincing results in SLE, a notoriously difficult disease to treat, Alumis may fail to establish the credibility of their TYK2 inhibitor approach and struggle to compete with other oral therapies in the market. Additionally, there is competition from other biopharmaceutical companies with similar therapies and Alumis may face challenges in commercializing their products without a suitable partner. Furthermore, any regulatory obstacles could lead to downward revisions in projections and impact the stock's performance.
This aggregate rating is based on analysts' research of Alumis Inc and is not a guaranteed prediction by Public.com or investment advice.
Alumis Inc (ALMS) Analyst Forecast & Price Prediction
Start investing in Alumis Inc (ALMS)
Order type
Buy in
Order amount
Est. shares
0 shares